Business
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the primer sets against the influenza A
About this update from Co-diagnostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the primer sets against the influenza A H3N2 subclade K.","length":583,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Co-Diagnostics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Co-Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":184,"url":"https://media.zenfs.com/en/prnewswire.com/7a89e790bf1cbdd13a473c00e9766ccb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_YQ2JYyHRV7RlBcYGBsF.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7a89e790bf1cbdd13a473c00e9766ccb","width":400,"height":184}},"href":"https://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"According to the World Health Organization, seasonal influenza causes approximately 3–5 million cases of severe illness annually, resulting in 290,000–650,000 respiratory fatalities. This year's flu vaccine is mismatched with subclade K (or "J.2.4.1"), which has limited natural immunity within communities. influenza A subtype H3N2 has historically been associated with higher rates of hospitalization and death, and preliminary data has already linked subclade K to countries like Japan and the United Kingdom experiencing earlier than usual flu seasons in 2025, following Australia reporting a record flu season.","length":629,"tagName":"p"},{"type":"text","content":""We have received customer inquiries regarding the performance of the Logix Smart ABC test against this year's influenza strains," remarked Dwight Egan, CEO of Co-Dx. "Based on the results of this analysis, we are confident that the test retains comparable sensitivity as when it was first developed on our proprietary platform more than five years ago. This consistency underscore...